RESEARCH PAPER
Immunity to hepatitis A virus among working professionals in Poland – Results of a 3-year serological survey 2013–2015
 
More details
Hide details
1
Department of Public Health, Medical University, Warsaw, Poland
2
Department of Health Economics and Medical Law, Medical University, Warsaw, Poland
3
Department of Economic and System Analysis, National Institute of Public Health – NIH, Warsaw, Poland
4
Department of Medicine and Health Sciences, Modrzewski Academy, Kraków, Poland
5
Department of Gynecology and Oncology, Jagiellonian University Medical College, Kraków, Poland
6
Department of Cancer Prevention, Medical University, Warsaw, Poland
7
National Institute of Public Health, Warsaw, Poland
CORRESPONDING AUTHOR
Aleksandra Izabela Czerw   

National Institute of Public Health, Poland, Warsaw, Zwirki i Wigury, 08-456 Warsaw, Poland
 
Ann Agric Environ Med. 2018;25(3):572–575
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Hepatitis A (HA) is caused by infection with the hepatitis A virus (HAV). The differential etiological diagnosis of acute hepatitis is based on a positive result of the serological test detecting IgM class anti-HAV. For epidemiological studies on past infection and seroprevalence of HAV in populations, the tests measuring IgG class anti-HAV or total anti-HAV are used. Since the 1990s, specific prophylaxis is possible by vaccination against HA. In Poland, vaccination is recommended and in majority is performed at own cost.

Material and methods:
Database was obtained from electronic medical records of the 2 major private health care providers networks (Luxmed and Medicover) operating in Poland. During a 3-year period (2013–2015), 1,124 persons with unknown status of anti-HA vaccination were tested for the presence of total anti-HAV. Objective. The aim of the study was to evaluate the seroprevalence of anti-HAV among working professionals in Poland.

Results:
Anti-HAV were detected in 603 (53.6%) persons, while 521 (46.3%) tested negative. The study group was divided into 2 subgroups: 25–44 and 45–64-years-old. For detailed statistical analysis, the presence of anti-HAV was considered as a dependent variable, and its predictors were gender, age and the year of the test performance. The presence of anti-HAV was significantly more prevalent in older age group. The lack of specific antibodies was more prevalent in younger age group.

Conclusions:
Results of the study show increasing susceptibility to HAV infection in the younger age group, compared with the older age group of corporate professional employees in large cities in Poland. Since the epidemiological situation of HA is currently changing with increasing number of symptomatic cases of HA, it is suggested that employers might consider including an additional procedure of vaccination against HA into their private health insurance portfolio.

 
REFERENCES (22)
1.
Lemon SM, Jansen RW, Brown EA. Genetic, antigenic and biological differences between strains of hepatitis A virus. Vaccine. 1992; Suppl 10: S40-S44.
 
2.
Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science. 1973; 182: 1026-1028.
 
3.
Ślusarczyk J, Hansson BG, Nordenfelt E, Krawczyński K, Karwowska S, Knap J. Etiopathogenetic Aspects of Hepatitis A. II. Specific and Non-specific Humoral Immune Response During the Course the Course of Infection. J Med Virol. 1984; 14: 269-276.
 
4.
Seeberg S, Brandberg A, Hermodsson S, Larsson P, Lundgren S. Hospital outbreak of hepatitis A secondary to blood exchange in the baby. Lancet. 1981; 1: 1155-1156.
 
5.
Barbara JAJ, Howell DR, Briggs M, Parry JV. Post-transfusion hepatitis A. Lancet. 1982; 1: 738.
 
6.
Perevoscikovs J, Lenglet A, Lucenko I, Stainerte A, Payne Hallstrom L, Coulombier D. Assessing the risk of a community outbreak of hepatitis A on blood safety in Latvia, 2008. Euro Surveill 2010; 14(3): pii=19092.
 
7.
Tong MJ, Thursby M, Rakela J, McPeak C, Edwards VM, Mosley JW. Studies on the maternal-infant transmission of the viruses which cause acute hepatitis. Gastroenterology. 1981; 80: 999-1004.
 
8.
Mindel A, Tedder R. Hepatitis A in homosexuals. Br Med J (Clin Res Ed). 1981; 282 (6277): 1666.
 
9.
Gossner CM, Severi E. Three simultaneous, food-borne, multi-country outbreaks of hepatitis A virus infection reported in EPIS-FWD in 2013: what does it mean for the European Union? Euro Surveill. 2014; 19(43):pii=20941.
 
10.
WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2012; 87(28-29): 261-276.
 
11.
Feinstone SM, Gust I. Hepatitis A vaccine. In: Vaccines. Ed. Plotkin S, Orenstein W.: 3rd ed. 1999: 650-672.
 
12.
Livni G, Plotkin S, Yuhas Y, Chodik G, Aloni H, Lerman Y, Ashkenazi S. Seroepidemiology of hepatitis A antibodies among children’s hospital staff. Pediatr Infect Dis J. 2002; 21(7): 618-622.
 
13.
Keeffe EB. Occupational risk for hepatitis A: a literature-base analysis. J Clin Gastroenterol. 2004; 38(5): 440-448.
 
14.
Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults. J Infect Dis. 2015; 212: 176-182.
 
15.
Świderska H, Ślusarczyk J. Viral hepatitis type A. Advances in diagnostic and epidemiological studies. Przegl Epidemiol. 1979; XXXIII, 3: 409-417.
 
16.
Polz-Dancewicz M, Policzkiewicz P, Badach Z. Changing epidemiology of hepatitis A virus infection – a comparative study in Central Eastern Poland (1990-1999). Med Sci Monit. 2000; 6(5): 989-993.
 
17.
Janaszek-Seydlitz W, Bucholc B, Wiatrzyk A. The level of antibodies against hepatitis A virus in persons from the Warsaw area. Przegl Epidemiol. 2007; 61: 675-682.
 
18.
Baumann-Popczyk A. Hepatitis A in Poland in 2013. Przegl Epidemiol. 2015; 69: 247-250.
 
19.
Polański P. Hepatitis A in Poland in 2014. Przegl Epidemiol. 2016; 70(2): 225-230.
 
20.
Polański P. Hepatitis A in Poland in 2015. Przegl Epidemiol. 2017, 71(3): 345-349.
 
21.
Personal communication with I. Paradowska-Stankiewicz Ph. D., the national consultant for epidemiology in Poland. 20/02/2018.
 
22.
ECDC. Communicable Disease Threats Report. Week 1, 31 December 2017 - 6 January 2018. Available at: https://ecdc.europa.eu/sites/p....
 
eISSN:1898-2263
ISSN:1232-1966